Wyślij emailem: NIMG-93. DISCRIMINATION OF CLINICALLY IMPACTFUL TREATMENT RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING BEVACIZUMAB TREATMENT